CN114814243B - Quantitative detection kit and method applied to protein antigen - Google Patents
Quantitative detection kit and method applied to protein antigen Download PDFInfo
- Publication number
- CN114814243B CN114814243B CN202210707753.0A CN202210707753A CN114814243B CN 114814243 B CN114814243 B CN 114814243B CN 202210707753 A CN202210707753 A CN 202210707753A CN 114814243 B CN114814243 B CN 114814243B
- Authority
- CN
- China
- Prior art keywords
- concentration detection
- detection zone
- signal
- antibody
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 114
- 102000036639 antigens Human genes 0.000 title claims abstract description 23
- 108091007433 antigens Proteins 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 13
- 239000012491 analyte Substances 0.000 claims description 35
- 239000004005 microsphere Substances 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000003908 quality control method Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The invention belongs to the technical field of in-vitro diagnosis and immunoassay, and provides a quantitative detection kit applied to protein antigens.
Description
Technical Field
The invention belongs to the technical field of in-vitro diagnosis and immunodetection, and particularly relates to a quantitative detection kit and a method applied to a protein antigen.
Background
An immunoassay method is commonly used for quantitative detection of protein antigens clinically, and the detection mode is a double-antibody sandwich method. The affinity of the paired antibodies in the double antibody sandwich method is a key factor determining the sensitivity of the assay and the detection range. The difference in affinity between the signal antibody and the coating antibody can determine the sensitivity and accuracy of the low region of the antigen to be detected. If a capture antibody with high affinity is used, the detection sensitivity can be improved, but a hook effect is easy to generate, and the upper limit of detection is reduced; the use of low affinity capture antibodies can broaden the upper detection limit of the detection method, but the detection sensitivity is low. And some special protein antigens, namely IGE, CEA, HCG, AFP, HBs and the like, have high requirements on functional sensitivity and detection range.
IgE is a secreted immunoglobulin that is present in very low levels in normal human serum (less than 0.001% of total serum immunoglobulin content). The IgE concentration in vivo is related to age, the content of newborn baby is lowest, and gradually increases with age, and reaches a stable level at 5-7 years, but reaches the highest content of IgE in the population of 10-15 years. IgE is mainly produced by plasma cells of the lamina propria at nasopharynx, tonsil, bronchus and the like, is a cytotropic antibody, and can be combined with IgE receptors on the surfaces of mast cells and basophils, so that the body is in a sensitized state. IgE is the primary antibody mediating type i hypersensitivity reactions, and the concentration of IgE in serum is often associated with the intensity of exposure to allergens and the severity of allergic symptoms. Serum IgE content measurement is often used for differential diagnosis and therapeutic efficacy monitoring of allergic diseases (such as asthma, hay fever, atopic dermatitis and urticaria) to distinguish between atopic and non-atopic allergic patients. Furthermore, accurate measurement of IgE concentration in serum during childhood is of great importance for predictive assessment of allergic symptoms. The upper limit of the detection range of the existing mainstream detection method is 2500IU/ml at most when the serum is not diluted again, and for the determination of high-level tIgE exceeding the upper limit of the detection, a specimen needs to be diluted and then determined, so that the workload of inspectors and the cost of reagents are increased, the determination time is long, and the rapid detection is not suitable.
Disclosure of Invention
The invention provides a quantitative detection kit aiming at the defects of the existing protein antigen immunodetection method, and when the kit is used for detecting the protein antigen, the kit has excellent sensitivity and wider detection range, and can meet two requirements of differential diagnosis and treatment curative effect monitoring of clinical patients.
In order to achieve the above objects, the present invention provides a quantitative assay kit for protein antigens, comprising a carrier, wherein a low concentration detection zone and a high concentration detection zone are sequentially disposed along a sample flow direction, the low concentration detection zone and the high concentration detection zone are capable of generating signals with different intensities based on the presence or absence of a target analyte, wherein the low concentration detection zone is coated with a capture antibody a, the high concentration detection zone is coated with a capture antibody B, and the affinity of the capture antibody a for the target analyte is higher than that of the capture antibody B for the target analyte.
In some embodiments of the invention, the signal antibody is an antibody labeled with a fluorescent microsphere, and the signal antibody and the capture antibody a or the capture antibody B simultaneously bind to the target analyte to form a sandwich complex with a fluorescent label.
In some embodiments of the present invention, the carrier is a microfluidic chip, the capture antibody a and the capture antibody B are sequentially coated in the microchannel along the sample flow direction to form a low concentration detection region and a high concentration detection region, and the signal antibody is disposed in the microchannel and located at the front end of the capture antibody a to form a label region or directly disposed in a sample addition hole of the microfluidic chip.
In some embodiments of the present invention, a labeling region, a low concentration detection region, a high concentration detection region, and a quality control region are sequentially disposed in the microchannel along the flow direction of the sample, and the quality control region is conventionally disposed.
In another aspect, the present invention also provides a method for quantitatively detecting protein antigens by using the kit of any one of the above technical solutions, comprising at least the following steps:
1) acquiring a calibration function;
2) adding a sample possibly containing a target analyte into a sample hole, firstly combining with a labeled antibody, sequentially flowing through a low-concentration detection area and a high-concentration detection area of a carrier, and acquiring a signal value of the low-concentration detection area and/or the high-concentration detection area by using a detection instrument after the reaction is finished;
3) determining the concentration of the target analyte in comparison to the calibration function: the concentration of the target analyte is determined using the calibration function T1 as a standard for the signal value from the lower concentration detection zone when only the low concentration detection zone detects a signal value, and the concentration of the target analyte is determined using the calibration function T2 as a standard for the signal value from the higher concentration detection zone when both the low concentration detection zone and the high concentration detection zone detect a signal.
The kit and the method applied to the protein antigen obtained by the technical scheme have the beneficial effects that:
1. the high-affinity capture antibody A and the low-affinity capture antibody B are sequentially arranged along the direction in which a sample flows, so that the antibodies with different affinities play different roles, the functional sensitivity is ensured, the detection range is widened, the accurate quantification of the protein antigen level with a large concentration range span is realized, and unnecessary dilution is reduced;
2. the micro-fluidic chip has small volume, consumes less reagent and sample, can complete the whole reaction process within 4 minutes, has simple operation and simple preparation of the chip at the early stage;
3. when determining the result, only the signal value of one of the lower concentration detection area and the high concentration detection area is needed to be determined separately, so that the analysis speed is improved.
Drawings
FIG. 1 is a structure of a kit for detecting IgE according to one embodiment of the present invention.
FIG. 2 is a test procedure using the kit of FIG. 1.
FIG. 3 shows the results of the test using the kit of FIG. 1.
Detailed Description
It should be noted that the embodiments and features of the embodiments of the present invention may be combined with each other without conflict.
Unless defined otherwise, technical terms used in the following examples have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods are conventional methods unless otherwise specified.
The present invention relates generally to the field of immunoassay technology, and more particularly, to a method for obtaining concentration information of a target analyte in a sample by sequentially passing the sample possibly containing the target analyte through a high-affinity capture antibody and a low-affinity capture antibody and generating a signal that can be captured, and using two capture antibodies with different affinities in combination to give play to their advantages.
The calibration function is a dose response curve measured by passing a concentration standard containing a series of target analyte through a high affinity capture antibody and a low affinity capture antibody in sequence, thereby inferring the concentration of the unknown sample.
The invention will be further explained with reference to examples and figures, it being understood that the invention is not limited to the specific embodiments described.
The invention provides a quantitative detection kit applied to a protein antigen, which comprises a carrier, wherein a low-concentration detection area (LT) and a high-concentration detection area (HT) are sequentially arranged on the carrier along the flow direction of a sample, the low-concentration detection area and the high-concentration detection area can generate signals with different intensities based on the existence or nonexistence of a target analyte, the low-concentration detection area is coated with a capture antibody A, the high-concentration detection area is coated with a capture antibody B, and the affinity of the capture antibody A for the target analyte is higher than that of the capture antibody B for the target analyte.
The low and high concentration detection zones generate a signal based on the sandwich of the target analyte, signal antibody and capture antibody, specifically from the signal carried by the signal antibody itself, which is captured by capture antibody a and/or capture antibody B after binding to the target analyte, to form an immobilized effective signal at the low and/or high concentration detection zones, such as the formation of an enzyme-labeled sandwich complex or the formation of a fluorescent microsphere-labeled sandwich complex, noting that the enzyme is capable of amplifying the target analyte chemical signal by converting the fifth to a detectable product.
In one embodiment, the signal antibody is an antibody labeled with a fluorescent microsphere, and the signal antibody and the capture antibody A or the capture antibody B are simultaneously bound with the target analyte to form a sandwich complex with a fluorescent label.
The signal antibody may be added dropwise to the carrier after mixing with the sample that may contain the target analyte, or may be provided at the front end of the low-concentration detection zone along the direction of flow of the sample to form a labeling zone.
The carrier can be a micro-fluidic chip driven by capillary force to drive a sample to flow or a chip driven by other mobile controllers to flow, and can also be a common detection test strip (comprising a sample loading pad, a marking pad, a chromatography pad and a sample sucking pad).
Specifically, the microfluidic chip comprises a microfluidic substrate and a microfluidic cover plate pressed on the microfluidic substrate, the substrate and the cover plate are enclosed to form a microchannel, one end of the microchannel is communicated with a sample adding hole formed in the cover plate, the other end of the microchannel is communicated with a waste liquid collecting pool, a marking area, a low concentration detection area (LT), a high concentration detection area (HT) and a quality control site C are sequentially arranged in the microchannel of the microfluidic substrate along the flow direction of a sample, a signal antibody marked with fluorescent microspheres is coated in the marking area, a capture antibody A is coated in the low concentration detection area, and a capture antibody B with low affinity relative to the capture antibody A is coated in the high concentration detection area.
The quality control site C is conventionally provided, for example, coated with an immobilized antigen that specifically binds to a signal antibody, and is used to determine whether the detection process is effective.
While figures 1-3 show a kit and process for detecting IgE using one of the embodiments of the present invention, it is to be understood that while the kit described herein is described for IgE determination, the kit described herein may also be used for content determination of protein antigens IgE, CEA, HCG, AFP, HBs, etc.
Taking IgE detection as an example, the signal antibody arranged in the labeling area of the carrier is an IgE antibody labeled by fluorescent microspheres, the high-affinity IgE monoclonal antibody a and the low-affinity IgE monoclonal antibody B are respectively coated in an LT area and an HT area after being coupled with biotin, and the IgE antigen is coated in a C area.
The serum to be detected is added into the sample adding hole and is driven by capillary force to enter the labeling area to be specifically combined with the fluorescent microsphere labeled IgE monoclonal antibody. The antigen-antibody compound continuously surges along the microchannel, and the high-affinity IgE monoclonal antibody A is encountered in the low-concentration detection area, so that the low-concentration IgE can be identified; if the content of IgE is too high, the excessive antigen-antibody complex continuously surges forwards to the high-concentration detection area to meet the low-affinity IgE monoclonal antibody B, and the paired antigen-antibody reaction plateau appears later, which is helpful for identifying the high-concentration IgE.
In another aspect, the present invention also provides a method for quantitatively detecting protein antigens by using the kit of any one of the above technical solutions, comprising at least the following steps:
1) obtaining a calibration function by sequentially flowing a concentration standard containing a target analyte through a low concentration detection zone and a high concentration detection zone to obtain a dose response curve, wherein the calibration function of the low concentration detection zone is T1, and the calibration function of the high concentration detection zone is T2;
2) combining a sample possibly containing a target analyte with a labeled antibody, sequentially flowing through a low-concentration detection area and a high-concentration detection area of a carrier (if the carrier is not provided with the labeled area, the sample needs to be mixed with the labeled antibody before being dripped into the carrier), and respectively acquiring signal values of the low-concentration detection area and the high-concentration detection area by using a detection instrument after the reaction is finished (the detection instrument is a conventional technology, such as a fluorescence detector, and is consistent with a signal carried by a signal antibody);
3) determining the concentration of the target analyte in comparison to the calibration function: when the signal value is detected at only the low concentration detection zone (lower target analyte concentration in the sample, complete capture of the target analyte-signal antibody bound complex by the target analyte and no signal from the high concentration detection zone), the concentration of the target analyte is determined using the calibration function T1 as a standard for the signal value at the lower concentration detection zone, and when the signal is detected at both the low and high concentration detection zones (higher target analyte concentration in the sample, insufficient capture antibody a to capture all of the target analyte-signal antibody bound complex, and no signal from the high concentration detection zone), the concentration of the target analyte is determined using the calibration function T2 as a standard for the signal value at the higher concentration detection zone.
It will be appreciated that the absence of a signal from the high concentration detection zone is relative, rather than absolute, and that when the signal from the high concentration detection zone is sufficiently weak compared to the signal from the low concentration detection zone, such as when the signal is fluorescence emitted by fluorescent microspheres, the signal from the high concentration detection zone is not visible to the naked eye, and the signal from the low concentration detection zone can be used to detect the signal from the low concentration detection zone, i.e., the concentration of the target analyte is still determined as the ratio of the signal from the low concentration detection zone to the calibration function T1; if the fluorescent signal from the high concentration detection zone is visible to the naked eye, a fluorescence detector may be used to detect the signal from the high concentration detection zone and the signal from the high concentration detection zone compared to the calibration function T2 to determine the concentration of the target analyte.
The detection method obtains the concentration of the target analyte by comparing the signal values of the low-concentration detection area and the high-concentration detection area with the calibration function, is simple to operate, does not need to carry out complex calculation, and has high analysis speed.
The technical solutions described above only represent the preferred technical solutions of the present invention, and some possible modifications to some parts of the technical solutions by those skilled in the art all represent the principles of the present invention, and fall within the protection scope of the present invention.
Claims (5)
1. The utility model provides a be applied to quantitative determination kit of protein antigen, includes the carrier, its characterized in that, set gradually low concentration detection zone and high concentration detection zone along the sample flow direction on the carrier, low concentration detection zone and high concentration detection zone can be based on the target analyte that is bound with signal antibody produces the signal of different intensity, wherein low concentration detection zone peridium has capture antibody A, and high concentration detection zone peridium has capture antibody B, and capture antibody A is higher than capture antibody B's affinity to the target analyte's affinity.
2. The quantitative detection kit applied to protein antigens as claimed in claim 1, wherein the signal antibody is an antibody labeled by fluorescent microspheres.
3. The quantitative detection kit applied to protein antigens as claimed in claim 1, wherein the carrier is a microfluidic chip, the capture antibody A and the capture antibody B are sequentially coated in a microchannel along a sample flowing direction to form a low concentration detection region and a high concentration detection region, and the signal antibody is disposed in the microchannel and positioned at the front end of the capture antibody A to form a labeling region or is directly disposed in a sample addition hole of the microfluidic chip.
4. The quantitative determination kit applied to protein antigens as claimed in claim 3, wherein a labeling zone, a low concentration detection zone, a high concentration detection zone and a quality control site are sequentially arranged in the micro-channel along the flow direction of the sample.
5. A method for the quantitative detection of protein antigens for non-diagnostic and non-therapeutic purposes, characterized in that the detection is carried out using a kit according to any one of claims 1 to 4, comprising at least the following steps:
1) acquiring a calibration function;
2) firstly, combining a sample possibly containing target analytes with a signal antibody, sequentially flowing through a low-concentration detection area and a high-concentration detection area of a carrier, and acquiring signal values of the low-concentration detection area and/or the high-concentration detection area by using a detection instrument after reaction;
3) determining the concentration of the target analyte in comparison to the calibration function: the concentration of the target analyte is determined using the calibration function T1 as a standard for the signal value from the lower concentration detection zone when only the low concentration detection zone detects a signal value, and the concentration of the target analyte is determined using the calibration function T2 as a standard for the signal value from the higher concentration detection zone when both the low concentration detection zone and the high concentration detection zone detect a signal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210707753.0A CN114814243B (en) | 2022-06-22 | 2022-06-22 | Quantitative detection kit and method applied to protein antigen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210707753.0A CN114814243B (en) | 2022-06-22 | 2022-06-22 | Quantitative detection kit and method applied to protein antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114814243A CN114814243A (en) | 2022-07-29 |
| CN114814243B true CN114814243B (en) | 2022-09-27 |
Family
ID=82522115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210707753.0A Active CN114814243B (en) | 2022-06-22 | 2022-06-22 | Quantitative detection kit and method applied to protein antigen |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114814243B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739042A (en) * | 1993-12-23 | 1998-04-14 | Sinvent As | Method of assay |
| WO1998036278A1 (en) * | 1997-02-15 | 1998-08-20 | Beth Israel Deaconess Medical Center, Inc. | Multiple-site antibody capture immunoassays and kits |
| US8354235B2 (en) * | 2004-05-12 | 2013-01-15 | Roche Diagnostics Operations, Inc. | Method for increasing the dynamic measuring range of test elements based on specific binding reactions |
| JP2016042030A (en) * | 2014-08-14 | 2016-03-31 | デンカ生研株式会社 | Method for expanding assayable range in immuno-chromatography |
| CN111707818A (en) * | 2020-06-16 | 2020-09-25 | 深圳市计量质量检测研究院（国家高新技术计量站、国家数字电子产品质量监督检验中心） | Immunochromatography detection card, preparation method and detection method |
| CN113634296A (en) * | 2021-10-19 | 2021-11-12 | 北京芯迈微生物技术有限公司 | Micro-fluidic chip |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2499831Y (en) * | 2001-09-26 | 2002-07-10 | 谢宗岑 | Detector |
| JP2006208386A (en) * | 2005-01-26 | 2006-08-10 | Agilent Technol Inc | Assay test strip with two or more markers, and reading method therefor |
| CN101275954B (en) * | 2008-05-09 | 2012-01-04 | 丁克祥 | Breast cancer early warning chip for easily rapid measuring human I type thymidine kinase gene protein |
| US8900881B2 (en) * | 2008-12-30 | 2014-12-02 | Jin Po Lee | Quantitative analyte assay device and method |
| CN102507944A (en) * | 2011-11-09 | 2012-06-20 | 河北省科学院生物研究所 | Reagent card for semiquantitatively detecting salbutamol |
| CN105823880B (en) * | 2016-03-21 | 2017-07-11 | 中国科学院理化技术研究所 | Biochip for expanding detection range by utilizing hook effect and detection method thereof |
| CN114324901B (en) * | 2022-03-07 | 2022-06-07 | 天津中新科炬生物制药股份有限公司 | Kit for expanding quantitative detection range and detection method |
-
2022
- 2022-06-22 CN CN202210707753.0A patent/CN114814243B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739042A (en) * | 1993-12-23 | 1998-04-14 | Sinvent As | Method of assay |
| WO1998036278A1 (en) * | 1997-02-15 | 1998-08-20 | Beth Israel Deaconess Medical Center, Inc. | Multiple-site antibody capture immunoassays and kits |
| US8354235B2 (en) * | 2004-05-12 | 2013-01-15 | Roche Diagnostics Operations, Inc. | Method for increasing the dynamic measuring range of test elements based on specific binding reactions |
| JP2016042030A (en) * | 2014-08-14 | 2016-03-31 | デンカ生研株式会社 | Method for expanding assayable range in immuno-chromatography |
| CN111707818A (en) * | 2020-06-16 | 2020-09-25 | 深圳市计量质量检测研究院（国家高新技术计量站、国家数字电子产品质量监督检验中心） | Immunochromatography detection card, preparation method and detection method |
| CN113634296A (en) * | 2021-10-19 | 2021-11-12 | 北京芯迈微生物技术有限公司 | Micro-fluidic chip |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114814243A (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106872420B (en) | Kit and method for time-resolved fluorescence quantitative detection of microalbuminuria | |
| Lin et al. | A nanoparticle label/immunochromatographic electrochemical biosensor for rapid and sensitive detection of prostate-specific antigen | |
| Tayyab et al. | Potential microfluidic devices for COVID-19 antibody detection at point-of-care (POC): A review | |
| Song et al. | Machine learning-based cytokine microarray digital immunoassay analysis | |
| KR102660904B1 (en) | Sandwich-type assay using a step to reduce the signal portion of the dose-response curve for measuring analytes, including those at high concentrations. | |
| WO2011016326A1 (en) | Method for detecting prozone phenomenon, analysis method, device for detecting prozone phenomenon and analyzer | |
| US6551788B1 (en) | Particle-based ligand assay with extended dynamic range | |
| JP3693680B2 (en) | Assays using magnetic particles | |
| Liu et al. | An improved portable biosensing system based on enzymatic chemiluminescence and magnetic immunoassay for biological compound detection | |
| Cai et al. | Lateral flow immunoassay based on gold magnetic nanoparticles for the protein quantitative detection: Prostate-specific antigen | |
| CN111684280B (en) | Lateral flow assay and method for detecting high concentration analytes | |
| JP2005510706A5 (en) | ||
| CN107121548A (en) | Quantitatively detect test paper, preparation method and the detection method of tumor markers | |
| CN114324901B (en) | Kit for expanding quantitative detection range and detection method | |
| CN113433329A (en) | PCT/IL-6 duplex detection kit based on quantum dot fluorescent microspheres and preparation method thereof | |
| JPWO2003029822A1 (en) | Specific binding analyzer and specific binding analysis method | |
| HK1250778A1 (en) | Analyte detection and methods | |
| CN112858699B (en) | Portable stress and mental illness objective index assessment test strip and method | |
| JP4972295B2 (en) | Immunoassay method and biochip | |
| Kawde et al. | Moving enzyme-linked immunosorbent assay to the point-of-care dry-reagent strip biosensors | |
| KR20160120675A (en) | Rapid Quantitative Diagnostic Kit | |
| Shin et al. | Hook effect detection and detection-range-controllable one-step immunosensor for inflammation monitoring | |
| CN114814243B (en) | Quantitative detection kit and method applied to protein antigen | |
| von Lode et al. | One-step quantitative thyrotropin assay for the detection of hypothyroidism in point-of-care conditions | |
| US20140011190A1 (en) | Method for performing a rapid test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |